Latest News

Kalbe Strengthen the Commercialization of Research in Indonesia

Kalbe Strengthen the Commercialization of Research in Indonesia

Press Release No. 048/KFCP-DIR/PR/XI/20

Jakarta, November 10, 2020 – PT Kalbe Farma Tbk (Kalbe) in collaboration with the Ministry of Research and Technology/National Agency for Research and Innovation (Kemenristek/BRIN) are conducting the Ristek/BRIN Kalbe Science Awards (RKSA) 2021 Program as an effort to strengthen the commercialization of research in Indonesia. The RKSA 2021 Program is a program that provides research funding for researchers in Indonesia using the theme of health, pharmaceutical, functional food, information technology, or life science. The research grants will be given to the best proposal that has been picked by the Juries of RKSA 2021, and the expected results can achieve the commercialization process to become a product or service that can be enjoyed by the general public.  At the same time, the 5 research results of the RKSA 2018 - 2020  research fund recipients that have undergone the monitoring and evaluation processes by the jury are also presented as a part of the RKSA 2018-2020 closing program. The RKSA event was attended by the Minister of Research and Technology/Chief of BRIN Prof. Bambang P.S. Brodjonegoro, Ph.D, as well as being part of the Indonesia Innovation Expo (IIE) 2020 series of activities that is organized by the Kemenristek/BRIN.

“Indonesia needs to transform from a resource-driven economy to innovation-driven economy where the acceleration of the recovery of the national economy should be based on the use of technology, and to turn Indonesia into a developed country by means of innovation and technology,“ said Minister of Research and Technology/Chief of BRIN Prof. Bambang P.S. Brodjonegoro, Ph.D in his speech at the launch of the RKSA 2021. 

The Minister of Research and Technology/BRIN, Prof Bambang  P.S Brodjonegoro, Ph.D, continued that the main keys to strengthening innovations are through the triple helix synergy; that includes researchers, innovators, academics, business folks as well as the technology manufacturing communities, and the government that shall support the implementation of research, and to create innovative products that will gradually provide independence for Indonesians; specifically in facing and preventing the spread of the Covid-19 Pandemic; as well as providing solutions for a plethora of issues - specifically in the fields of health, economics, and education. 

“RKSA or Ristek BRIN Kalbe Science Awards is the result of the collaboration of the Kemenristek/BRIN and Kalbe in improving the commercial of the researches in the field of health that shall also strengthen the collaboration between Academics, Industry, Government, and other Research Communities. Commercialization the researches will positively contribute to the improvement of health services for the community and the value increase of the national economy,” said Vidjongtius, Director of PT Kalbe Farma Tbk. “Kalbe continues to be committed to continue RKSA for the 7th time in year 2021 by providing research funding for research proposals in the field of health, and will give special attention to researches that are related to Covid-19,” said Vidjongtius.

“The Research process is to find a novel mean, thus when the research has been through the process of invention and innovation, the most important thing afterward is the process of  commercialization.  For the downstreaming element, the business elements or corporations have the major role in order for the researches conducted by academics can be tangibly enjoyed by the public.  The government as a policy holder also has a major role in expediting the process of research in Indonesia,“ said dr. Boenjamin Setiawan, Ph.D - Founder of PT Kalbe Farma Tbk. 

“We hope that the RKSA program could support the research products that are downstream-ready, especially researches with TRL of above 5. Therefore the RKSA can encourage researchers to be more active in translating their research results into products or goods or services that can be utilized by the public,“ said Prof. Dr. Amin Subandrio, PhD, Sp.MK, Chairman of the Board of the Jury of RKSA 2018-2020. 

“In this event, Kalbe will also continue the downstreaming process on the research of Prof. Dr. Ir. Made Astawan, MS., from Bogor Institute of Agriculture with the theme of the Utilization of Fresh Tempeh, Semangit, and Bosok made from Germinated Soy As Functional Food for Hypoglycemia,“ said Pre Agusta, R & D Director of PT Kalbe Farma Tbk, who also represents the RKSA 2021 committee. “We hope the downstreaming process can manifest a product that can be enjoyed by the public,” said Pre Agusta again.

Further Pre Agusta explained the processes of RKSA 2021 that will take several stages, i.e. from the acceptance of the research proposals stage on January-April 2021, followed by the judgment of the proposals on May-June 2021.  The next stage is the presentation of the selected proposals in August 2021 and the announcement of the research proposals that will receive the research grant in September 2021. For the year afterward the research will undergo monitoring and evaluation processes done by the Jury of RKSA 2021.

The Board of Juries of RKSA 2021 consists of Prof. Dr. Amin Soebandrio, Ph.D, Sp.MK., (Director of the Eijkman Molecular Biology Agency), Dr.  Ir. Bambang Setiadi, IPU - (Chairman of the National Research Board), Dr. Ir.  Roy Alexander Sparringa, M. App.SC. (Senior Advisor of BPPT), Dr. Lucia Rizka Andalusia, Apt,. 
M. Pharm, MARS, (Director of Drug Registrations of the Drug and Food Supervisory Agency), dr. Sandy Qlintang (Director of the Stem Cell and Cancer Institute & Pharma Metric Labs of PT Kalbe Farma Tbk), as well as the Honorary Jury from the Ministry of Research and Technology/BRIN and Founder of PT Kalbe Farma Tbk Dr. Boenjamin Setiawan, Ph.D.

The researchers of RKSA 2018-2020 that have been selected through monitoring and evaluation that are present at the launch of the RKSA 2021 event, are (1) Dr. Anggraini Barlian with the research title of Application of Micropatterning to Increase the Proliferation and Differentiation of Human Wharton's Jelly Mesenchymal Stem Cells,  (2) Dessy Natalia, Ph.D with the research title of Improvement of the Performance of the Rapid Detection Test Equipment of Dengue Fever Through a Variety of Components of the Dengue Antigen,  (3) Dr. dr. Ariandi, SpOT(K) with the research title of Effectiveness and Safety of Therapy of Mesenchymal Stem Cells in Patients with Degeneration of The Intervertebral discs,  (4) Prof. Dr. Ir. Made Astawan, MS, with the research title of Utilization of Fresh Tempeh, Semangit, and Bosok made from Germinated Soy As Functional Food for Hypoglycemia, and  (5) Prof. Dr. Endang Sutriswati Rahayu, MS with the research title of Effect of the Consumption of Indigenous Probiotic Powder in Overcoming Obesity.

Information and registration of participants of the RKSA 2021 program can be seen in

Kalbe at a glance
PT Kalbe Farma Tbk ("Kalbe") was established in 1966 and is one of the largest listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines (Cefspan, Brainact, Broadced, etc.); health product division that handles over-the-counter medications (Promag, Mixagrip, Komix, Woods, Fatigon, etc.); energy and ready-to-consume drinks (Hydro Coco, Extra Joss, Nitros); nutrition division (ChilKid, Prenagen, Diabetasol, etc.); and distribution division. Kalbe presently has 43 subsidiaries and 15 international standard production facilities, employs approximately 16,000 employees and has 76 distribution & logistics branches throughout Indonesia. Since 1991, Kalbe is listed on the Indonesia Stock Exchange (IDX: KLBF).


305 Rate this article:
No rating

Please login or register to post comments.